| Title |
Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial
|
|---|---|
| Published in |
Intensive Care Medicine, September 2016
|
| DOI | 10.1007/s00134-016-4465-6 |
| Pubmed ID | |
| Authors |
The IRONMAN Investigators, Edward Litton, Stuart Baker, Wendy N. Erber, Shannon Farmer, Janet Ferrier, Craig French, Joel Gummer, David Hawkins, Alisa Higgins, Axel Hofmann, Bart De Keulenaer, Julie McMorrow, John K. Olynyk, Toby Richards, Simon Towler, Robert Trengove, Steve Webb, The Australian and New Zealand Intensive Care Society Clinical Trials Group |
| Abstract |
Both anaemia and allogenic red blood cell transfusion are common and potentially harmful in patients admitted to the intensive care unit. Whilst intravenous iron may decrease anaemia and RBC transfusion requirement, the safety and efficacy of administering iron intravenously to critically ill patients is uncertain. The multicentre, randomized, placebo-controlled, blinded Intravenous Iron or Placebo for Anaemia in Intensive Care (IRONMAN) study was designed to test the hypothesis that, in anaemic critically ill patients admitted to the intensive care unit, early administration of intravenous iron, compared with placebo, reduces allogeneic red blood cell transfusion during hospital stay and increases the haemoglobin level at the time of hospital discharge. Of 140 patients enrolled, 70 were assigned to intravenous iron and 70 to placebo. The iron group received 97 red blood cell units versus 136 red blood cell units in the placebo group, yielding an incidence rate ratio of 0.71 [95 % confidence interval (0.43-1.18), P = 0.19]. Overall, median haemoglobin at hospital discharge was significantly higher in the intravenous iron group than in the placebo group [107 (interquartile ratio IQR 97-115) vs. 100 g/L (IQR 89-111), P = 0.02]. There was no significant difference between the groups in any safety outcome. In patients admitted to the intensive care unit who were anaemic, intravenous iron, compared with placebo, did not result in a significant lowering of red blood cell transfusion requirement during hospital stay. Patients who received intravenous iron had a significantly higher haemoglobin concentration at hospital discharge. The trial was registered at http://www.anzctr.org.au as # ACTRN12612001249842. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 21% |
| United Kingdom | 5 | 17% |
| Malaysia | 2 | 7% |
| Australia | 2 | 7% |
| Netherlands | 1 | 3% |
| Switzerland | 1 | 3% |
| South Africa | 1 | 3% |
| Singapore | 1 | 3% |
| Denmark | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 7 | 24% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 19 | 66% |
| Practitioners (doctors, other healthcare professionals) | 6 | 21% |
| Scientists | 3 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | <1% |
| Unknown | 129 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 18 | 14% |
| Researcher | 14 | 11% |
| Professor > Associate Professor | 10 | 8% |
| Student > Bachelor | 10 | 8% |
| Student > Master | 10 | 8% |
| Other | 36 | 28% |
| Unknown | 32 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 78 | 60% |
| Nursing and Health Professions | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Engineering | 2 | 2% |
| Sports and Recreations | 1 | <1% |
| Other | 3 | 2% |
| Unknown | 35 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2023.
All research outputs
#1,695,249
of 24,814,419 outputs
Outputs from Intensive Care Medicine
#1,412
of 5,320 outputs
Outputs of similar age
#29,932
of 329,297 outputs
Outputs of similar age from Intensive Care Medicine
#15
of 116 outputs
Altmetric has tracked 24,814,419 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,320 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.4. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,297 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.